|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tafinlar
|
|
gptkbp:can_be_combined_with
|
gptkb:trametinib
|
|
gptkbp:chemical_formula
|
C23 H22 F3 N5 O
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
targeted therapy
|
|
gptkbp:contraindication
|
hypersensitivity to dabrafenib
|
|
gptkbp:discovery_year
|
gptkb:2013
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dabrafenib
|
|
gptkbp:indication
|
gptkb:BRAF_V600_E_mutation-positive_tumors
|
|
gptkbp:interacts_with
|
strong CYP3 A4 inducers
strong CYP3 A4 inhibitors
|
|
gptkbp:lifespan
|
8 hours
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:mechanism_of_action
|
BRAF inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:project
|
approved
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
eye examinations
liver function tests
skin examinations
|
|
gptkbp:side_effect
|
gptkb:muscular_dystrophy
gptkb:anemia
gptkb:cutaneous_squamous_cell_carcinoma
fatigue
headache
nausea
fever
diarrhea
rash
gastrointestinal perforation
joint pain
dehydration
peripheral neuropathy
liver enzyme elevation
severe allergic reactions
anaphylaxis
thrombocytopenia
pulmonary embolism
venous thromboembolism
hyperglycemia
neutropenia
hypersensitivity reactions
severe infections
hypophosphatemia
cardiac events
rhabdomyolysis
pyrexia
severe skin reactions
ocular toxicity
musculoskeletal pain
hypomagnesemia
hypocalcemia
fatigue-related events
serious skin reactions
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:BRAF_V600_E_mutation
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Tafinlar
|
|
gptkbp:bfsLayer
|
5
|